Skip to main content

Table 1 Demographic backgrounds of the patients studied

From: What range of extra-cardiac conduit flow velocity is detectable intraoperatively following the completion of a total cavo-pulmonary connection?

Case Age (mo) BW (kg) BSA (m2) Diagnosis Interval from BDG (mo) Fenestration ECC (mm) Predicted m-V IVC (mm) Pharmacol. support (γ) sBP CVP rSO2 ScvO2 Measured m-V
A B M N
1 55 13.0 0.58 SLV 47 + 18 10.9 14.3 4 3 0.5 2 85 16.5 74.1 20.0
2 31 12.8 0.54 SLV 14 18 8.5 10.0 5 2 0.5 3 95 16 71.4 17.0
3 28 10.4 0.48 HLHS 14 16 9.7 9.8 4 5 0.5 2 105 16 86.9 38.3
4 54 14.4 0.63 d-TGA, PS 14 16 14.6 9.6 5 0 0.5 3 75 13.5 81/83 81.6 34.7
5 60 18.6 0.72 TA 55 + 18 13.4 10.0 5 2 0.5 3 90 16 85/89 36.3
6 37 12.2 0.55 unbalanced AVSD 15 16 11.5 7.2 3 0 0.5 1 90 14.5 78/80 18.7
7 29 11.2 0.50 SLV, DORV, AVSD 13 16 10.0 7.0 5 0 0.5 1 80 15 86/83 19.0
8 27 10.0 0.46 Ebstein’s anomaly 18 + 16 9.4 5.9 4 0 0.5 1 80 15 74/67 56.7
  1. mo months, BW body weight, BSA body surface area, BDG bidirectional Glenn, ECC extra-cardiac conduit, m-V mean velocity, IVC inferior vena cava, pharmacol. pharmacological, γ μg/kg/min, A dopamine, B dobutamine, M milrinone, N nitroglycerine, sBP systolic blood pressure, CVP central venous pressure, rSO 2 cerebral regional oxygen saturation, ScvO 2 central venous oxygen saturation, SLV single left ventricle, HLHS hypoplastic left heart syndrome, TGA transposition of the great arteries, PS pulmonary stenosis, TA tricuspid atresia, AVSD atrioventricular septal defect, DORV double outlet from right ventricle